Industry
Biotechnology
Opthea Limited, a clinical stage biopharmaceutical company, develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead asset is OPT 302, a soluble form of VEGFR 3 in clinical development as a novel therapy for wet neovascular age related macular degeneration and diabetic macular edema DME, as well as a first in class VEGF C/D inhibitors for treatment with VEGF A inhibitors for the treatment of wet neovascular AMD and other retinal diseases. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Insights
December 27, 2023 | 1:07 pm
Portfolio Pulse from Benzinga Newsdesk
December 27, 2023 | 11:02 am
Portfolio Pulse from Benzinga Newsdesk
December 19, 2023 | 11:02 am
Portfolio Pulse from Benzinga Newsdesk
October 27, 2023 | 9:39 am
Portfolio Pulse from Benzinga Newsdesk
September 13, 2023 | 4:25 pm
Portfolio Pulse from Lisa Levin
August 28, 2023 | 5:52 pm
Portfolio Pulse from Benzinga Newsdesk
August 28, 2023 | 9:34 am
Portfolio Pulse from richadhand@benzinga.com
August 01, 2023 | 10:17 am
Portfolio Pulse from Benzinga Newsdesk
July 26, 2023 | 10:06 am
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.